Society of Nuclear Medicine Offers Online CME

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

RESTON, Virginia-The Society of Nuclear Medicine (SNM) has formed an online collaboration with Medscape, a website for health care professionals and consumers, to release an educational program highlighting key content from the SNM’s 2001 annual conference.

RESTON, Virginia—The Society of Nuclear Medicine (SNM) has formed an online collaboration with Medscape, a website for health care professionals and consumers, to release an educational program highlighting key content from the SNM’s 2001 annual conference.

This free CME program, available on Medscape (www.medscape.com), showcases scientific articles covering core topics of interest to nuclear medicine specialists and specialty physicians. The program has been approved for 2 Category 1 CME credits by the SNM.

In a separate news release, the Society announced that webcasts of sessions from the annual conference are available in the SNM Virtual Library, produced by DigiScript. The cost, including CME credits, is $25 for members and $40 for nonmembers. To subscribe, go to www.snm.org. 

Articles in this issue
Elderly Colon Cancer Patients Benefit From Adjuvant Chemotherapy
Stromal Cells May Be Involved in Development of Breast Carcinoma
Intercultural Facts About Cancer
Nurse-Provided Education Crucial to Sural Nerve Graft Prostatectomy Patients
18-Gene Cluster Found in ER-Positive Breast Cancers
Viread OK’d for Treating HIV With Other Antiretrovirals
Surgeons in New York Operate on Patient in France
Fulvestrant Reduces Cell Turnover Index More Than Tamoxifen
New Lung Cancer Campaign Launched
CPDR Updates Its Prostate Cancer Website
NIAID Begins Phase I Trial of a DNA-Based HIV Vaccine
PET Used to Measure Efficacy of an Angiogenesis Inhibitor
Avon Donates $20 Million to NCI for Cancer Research
Weekly Gemcitabine/Vinorelbine Proves Effective in NSCLC
Supplemental NDA Submitted for Gleevec

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content
Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission

Russ Conroy
August 5th 2025
Article

Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 5th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Roman Fabbricatore
August 5th 2025
Article

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 5th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

INKmune Exhibits Favorable Safety in Metastatic CRPC

Roman Fabbricatore
August 5th 2025
Article

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.

Aumolertinib Has Long-Term Survival Benefit in NSCLC With Brain Metastases

Russ Conroy
August 5th 2025
Article

Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.